1746 KB25 KB200520252023Avsec, DamjanMlinarič-Raščan, IrenaPodgornik, HelenaŠkerget, Matevžštevilka:1letnik:74str. 67-74ISSN:0014-8229COBISSID_HOST:144693763URN:URN:NBN:SI:doc-3U3XM157slSlovensko farmacevtsko društvoFarmacevtski vestnikduvelizibidelalizibKronična limfocitna levkemijaPI3KZdravljenjeTarčno zdravljenje kronične limfocitne levkemije z zaviralci fosfatidilinozitol 3-kinaze targeting| Phosphatidylinositol 3-kinase in chronic lymphocytic leukemia|Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in Slovenia. Since 2014, target therapies have been available for the treatment of CLL. Inhibitors of the B-cell receptor signalling pathway, which include inhibitors of Bruton tyrosine kinase and inhibitors of phosphatidylinositol 3-kinase (PI3K), and Bcl-2 antagonists are important drugs currently available for the treatment of relapsed/refractory CLL. In this paper, we review approved and developing PI3K inhibitors and less researched but important drugs that target Syk and Lyn. We present their clinical development and provide an outlook for using these drugs in the therapy of CLLKronična limfocitna levkemija (KLL) je najpogostejša levkemija pri odraslih v Sloveniji. Od leta 2014 so za zdravljenje KLL na voljo tarčna zdravila. Zaviralci receptorske poti celic B, ki jih delimo na zaviralce Brutonove tirozin kinaze in na zaviralce fosfatidilinozitol 3-kinaze (PI3K), in antagonisti Bcl-2 predstavljajo pomembne učinkovine za zdravljenje ponovljene/neodzivne KLL. V tem članku smo naredili pregled odobrenih in zaviralcev PI3K v razvoju ter manj raziskanih, vendar pomembnih učinkovin, ki ciljajo tirozin kinazi Syk in Lyn. Predstavili smo njihov klinični razvoj in prihodnost za zdravljenje bolnikov s KLLTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo